Context Therapeutics Inc. announced its financial results for the second quarter ended June 30, 2025, on August 6, 2025. The company reported cash and cash equivalents of $83.5 million as of June 30, 2025, and expects this to fund operations into 2027.
The company confirmed that its CTIM-76 and CT-95 Phase 1 dose-escalation studies are ongoing. Context expects to share initial dose escalation data for the CTIM-76 trial in the second quarter of 2026 and for the CT-95 trial by mid-2026.
Additionally, Context expects to complete necessary regulatory filings to support the initiation of a first-in-human trial for CT-202, a Nectin-4 x CD3 bispecific antibody, in the second quarter of 2026. This progress reinforces the company's commitment to advancing its portfolio of T cell-engaging therapies for solid tumors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.